To our knowledge, ODF2L is a scaffold protein with no commercially available inhibitor; therefore, we used the targeted RNAi therapeutic lipid nanoparticle (LNP) platform called ASSET (anchored secondary scFv enabling targeting) to specifically knock down ODF2L in ID8 cancer cells in vivo (30, 31). This evidence concerns the gene ODF2L and cancer.